Page 91 - Read Online

Page 20 of 26 Skorupan et al. J Cancer Metastasis Treat 2023;9:5 https://dx.doi.org/10.20517/2394-4722.2022.106

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med
2011;364:1817-25. DOI
2. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med
2018;379:2395-406. DOI PubMed
3. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced
pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29:4548-54. DOI PubMed PMC
4. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy
in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017;389:1011-
24. DOI PubMed
5. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7-33. DOI PubMed
6. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the
unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913-21. DOI PubMed
7. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin 2021;71:209-49. DOI PubMed
8. Gordon-Dseagu VL, Devesa SS, Goggins M, Stolzenberg-Solomon R. Pancreatic cancer incidence trends: evidence from the
surveillance, epidemiology and end results (SEER) population-based data. Int J Epidemiol 2018;47:427-39. DOI PubMed PMC
9. Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional
pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 2016;103:153-71.
DOI PubMed PMC
10. Holly EA, Chaliha I, Bracci PM, Gautam M. Signs and symptoms of pancreatic cancer: a population-based case-control study in the
San Francisco Bay area. Clin Gastroenterol Hepatol 2004;2:510-7. DOI PubMed
11. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol 2004;5:655-63. DOI PubMed
12. Artinyan A, Soriano PA, Prendergast C, Low T, Ellenhorn JD, Kim J. The anatomic location of pancreatic cancer is a prognostic
factor for survival. HPB 2008;10:371-6. DOI PubMed PMC
13. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent
resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267-77. DOI PubMed
14. Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline
resectable pancreatic cancer: long-term results of the dutch randomized preopanc trial. J Clin Oncol 2022;40:1220-30. DOI PubMed
15. Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline
resectable pancreatic cancer: results of the dutch randomized phase III preopanc trial. J Clin Oncol 2020;38:1763-73. DOI PubMed
PMC
16. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med
2013;369:1691-703. DOI PubMed PMC
17. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for
patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13. DOI PubMed
18. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med
2012;366:2455-65. DOI
19. O’Reilly EM, Oh DY, Dhani N, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal
adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol 2019;5:1431-8. DOI PubMed PMC
20. Hu ZI, Shia J, Stadler ZK, et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and
recommendations. Clin Cancer Res 2018;24:1326-36. DOI PubMed PMC
21. Humphris JL, Patch AM, Nones K, et al. Hypermutation in pancreatic cancer. Gastroenterology 2017;152:68-74.e2. DOI PubMed
22. Bian J, Almhanna K. Pancreatic cancer and immune checkpoint inhibitors-still a long way to go. Transl Gastroenterol Hepatol
2021;6:6. DOI PubMed PMC
23. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical
barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21:418-29. DOI PubMed PMC
24. Truong LH, Pauklin S. Pancreatic cancer microenvironment and cellular composition: current understandings and therapeutic
approaches. Cancers 2021;13:5028. DOI PubMed PMC
25. Jaffee EM, Hruban RH, Canto M, Kern SE. Focus on pancreas cancer. Cancer Cell 2002;2:25-8. DOI PubMed
26. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.